Monocyte/Macrophages And Their Role In Hiv Neuropathogenesis

Immunological Reviews

Volumn 254, Issue 1, 2013, Pages 102-113

  Burdo, Tricia H ^a   Lackner, Andrew ^b   Williams, Kenneth C ^a  

^a BOSTON COLLEGE   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

AIDS; Immunodeficiency diseases; Monocyte macrophages

Indexed keywords

ACUTE PHASE PROTEIN; ANTIVIRUS AGENT; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; D DIMER; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEOPTERIN;

ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CELL POPULATION; CENTRAL NERVOUS SYSTEM INFECTION; GIANT CELL; HEART DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLAMMATORY CELL; MACROPHAGE; METABOLIC SYNDROME X; MICROGLIA; MONOCYTE; NERVE CELL; NERVE CELL LESION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD;

ACUTE-PHASE PROTEINS; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM DISEASES; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; MACROPHAGES; METABOLIC SYNDROME X; MONOCYTES; PHENOTYPE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

EID: 84879302155     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12068     Document Type: Article

References (146)

1. Williams KC, et al. Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 2001;193:905-915.
2. Bell JE. The neuropathology of adult HIV infection. Rev Neurol 1998;154:816-829.
3. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988;319:1573-1578.
4. Heaton RK, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011;17:3-16.
5. Heaton RK, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75:2087-2096.
6. Marra CM, Lockhart D, Zunt JR, Perrin M, Coombs RW, Collier AC. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003;60:1388-1390.
7. Robertson KR, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004;36:562-566.
8. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-1738.
9. Sacktor N, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology 2001;56:257-260.
10. Mocroft A, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 2000;14:1545-1552.
11. Antinori A, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799.
12. Marra CM, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23:1359-1366.
13. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006;66:1447-1450.
14. Robertson KR, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21:1915-1921.
15. Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurol 2011;17:176-183.
16. Heaton RK, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004;10:317-331.
17. Eden A, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010;202:1819-1825.
18. Canestri A, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010;50:773-778.
19. Peluso MJ, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 2012;26:1765-1774.
20. Lentz MR, et al. Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology 2009;72:1465-1472.
21. Lentz MR, et al. Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain. Radiology 2005;235:461-468.
22. Gonzalez RG, et al. New insights into the neuroimmunity of SIV infection by magnetic resonance spectroscopy. J Neuroimmune Pharmacol 2006;1:152-159.
23. Chakrabarti L, et al. Early viral replication in the brain of SIV-infected rhesus monkeys. Am J Pathol 1991;139:1273-1280.
24. Hurtrel B, Chakrabarti L, Hurtrel M, Maire MA, Dormont D, Montagnier L. Early SIV encephalopathy. J Med Primatol 1991;20:159-166.
25. Davis LE, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992;42:1736-1739.
26. An SF, Groves M, Gray F, Scaravilli F. Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. J Neuropathol Exp Neurol 1999;58:1156-1162.
27. Ances BM, et al. Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 2009;73:702-708.
28. Moller HJ. Soluble CD163. Scand J Clin Lab Invest 2011;72:1-13.
29. Burdo TH, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 2011;204:154-163.
30. Ellis RJ, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011;25:1747-1751.
31. Spudich SS, Ances BM. Neurologic complications of HIV infection. TopAntiviral Med 2012;20:41-47.
32. Childs EA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52:607-613.
33. Letendre S, Ellis R. Viral and cellular biomarkers during antiretroviral therapy. In: Gendelman HE, Grant I, Everall I, Fox HS, Gelbard HA, Lipton SA, Swindells S, eds. The Neurology of AIDS. 3rd edn. Oxford: Oxford University Press, 2012:825-846.
34. Elovaara I, et al. CSF and serum beta-2-microglobulin in HIV infection related to neurological dysfunction. Acta Neurol Scand 1989;79:81-87.
35. McArthur JC, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997;42:689-698.
36. Sonnerborg AB, von Stedingk LV, Hansson LO, Strannegard OO. Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS 1989;3:277-283.
37. Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis 1996;174:294-298.
38. Ryan LA, et al. Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis 2001;184:699-706.
39. Ancuta P, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE 2008;3:e2516.
40. Cinque P, et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 1998;12:1327-1332.
41. Conant K, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 1998;95:3117-3121.
42. Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 1998;44:831-835.
43. Zink MC, Clements JE. A novel simian immunodeficiency virus model that provides insight into mechanisms of human immunodeficiency virus central nervous system disease. J Neurovirol 2002;8(Suppl):42-48.
44. Mankowski JL, Queen SE, Clements JE, Zink MC. Cerebrospinal fluid markers that predict SIV CNS disease. J Neuroimmunol 2004;157:66-70.
45. Sun B, Abadjian L, Rempel H, Calosing C, Rothlind J, Pulliam L. Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. J Neurovirol 2010;16:115-124.
46. Burdo TH, Weiffenbach A, Woods S, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 is a marker of neurocognitive impairment in HIV infection. AIDS 2013. [Epub ahead of print].
47. Burdo T, Weiffenbach A, Woods S, Letendre S, Ellis R, Williams K. Elevated sCD163 is a marker of neurocognitive impairment in HIV-infected individuals on effective ART. 19th Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, Washington: Washington State Convention Center, 2012.
48. Williams KC, Hickey WF. Traffic of hematogenous cells through the central nervous system. Curr Top Microbiol Immunol 1995;202:221-245.
49. Fischer-Smith T, et al. CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol 2001;7:528-541.
50. Kim WK, Corey S, Alvarez X, Williams K. Monocyte/macrophage traffic in HIV and SIV encephalitis. J Leukoc Biol 2003;74:650-656.
51. Clay CC, et al. Neuroinvasion of fluorescein-positive monocytes in acute simian immunodeficiency virus infection. J Virol 2007;81:12040-12048.
52. Fischer-Smith T, Bell C, Croul S, Lewis M, Rappaport J. Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J Neurovirol 2008;14:318-326.
53. Burdo TH, et al. Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog 2010;6:e1000842.
54. Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 2005;111:194-213.
55. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005;5:69-81.
56. Cinque P, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 1998;12:389-394.
57. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995;38:755-762.
58. Gartner S. HIV infection and dementia. Science 2000;287:602-604.
59. Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet 1997;349:692-695.
60. Fischer-Smith T, Tedaldi EM, Rappaport J. CD163/CD16 coexpression by circulating monocytes/macrophages in HIV: potential biomarkers for HIV infection and AIDS progression. AIDS Res Hum Retroviruses 2008;24:417-421.
61. Ratto-Kim S, et al. Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand. J Neuroimmunol 2008;195:100-107.
62. Kim WK, et al. Monocyte heterogeneity underlying phenotypic changes in monocytes according to SIV disease stage. J Leukoc Biol 2010;87:557-567.
63. Crowe S, Zhu T, Muller WA. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol 2003;74:635-641.
64. Ellery PJ, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 2007;178:6581-6589.
65. Thieblemont N, Weiss L, Sadeghi HM, Estcourt C, Haeffner-Cavaillon N. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol 1995;25:3418-3424.
66. Hasegawa A, et al. The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood 2009;114:2917-2925.
67. Mayne E, et al. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquired Immun Def Syndromes 2012;59:340-346.
68. Funderburg NT, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010;115:161-167.
69. Burdo TH, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011;204:1227-1236.
70. Pereyra F, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012;26:2409-2412.
71. Subramanian S, et al. Arterial inflammation in patients with HIV. JAMA 2012;308:379-386.
72. Arildsen H, Sorensen KE, Ingerslev JM, Ostergaard LJ, Laursen AL. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013;14:1-9.
73. Funderburg NT, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 2012;120:4599-4608.
74. Bellacosa C, et al. Carotid intima media thickness changes, endothelial activation and inflammatory markers in advanced naive HIV patients starting antiretroviral therapy. J Int AIDS Soc 2012;15:18153.
75. Armah KA, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012;55:126-136.
76. Duprez DA, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS ONE 2012;7:e44454.
77. Ford ES, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010;24:1509-1517.
78. Kuller LH, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203.
79. Lopez M, San Roman J, Estrada V, Vispo E, Blanco F, Soriano V. Endothelial Dysfunction in HIV Infection - The Role of Circulating Endothelial Cells, Microparticles, Endothelial Progenitor Cells and Macrophages. AIDS Rev 2012;14:223-230.
80. Yearley JH, Pearson C, Shannon RP, Mansfield KG. Phenotypic variation in myocardial macrophage populations suggests a role for macrophage activation in SIV-associated cardiac disease. AIDS Res Hum Retrovirus 2007;23:515-524.
81. Kelly KM, et al. Diastolic dysfunction is associated with myocardial viral load in simian immunodeficiency virus-infected macaques. AIDS 2012;26:815-823.
82. Roberts ES, Masliah E, Fox HS. CD163 identifies a unique population of ramified microglia in HIV encephalitis (HIVE). J Neuropathol Exp Neurol 2004;63:1255-1264.
83. Kim WK, et al. CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am J Pathol 2006;168:822-834.
84. Soulas C, et al. Recently infiltrating MAC387(+) monocytes/macrophages a third macrophage population involved in SIV and HIV encephalitic lesion formation. Am J Pathol 2011;178:2121-2135.
85. Walker J, et al. Elevated numbers of CD163+ macrophages in hearts of SIV+ rhesus macaques with cardiac disease are decreased using PA300. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, 2013.
86. Williams K, et al. Proliferating cellular nuclear antigen expression as a marker of perivascular macrophages in simian immunodeficiency virus encephalitis. Am J Pathol 2002;161:575-585.
87. Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 2002;25:537-562.
88. Williams KC, Hickey WF, Burdo TH, Soulas C. Mononuclear phagocytes. In: Gendleman HEGI, Everall IP, Fox HS, Gelbard HA, Lipton SA, Swindells S, eds. The Neurology of AIDS. Oxford: Oxford University Press, 2012.
89. Kim WK, Avarez X, Williams K. The role of monocytes and perivascular macrophages in HIV and SIV neuropathogenesis: information from non-human primate models. Neurotox Res 2005;8:107-115.
90. Borda JT, et al. CD163, a marker of perivascular macrophages, is up-regulated by microglia in simian immunodeficiency virus encephalitis after haptoglobin-hemoglobin complex stimulation and is suggestive of breakdown of the blood-brain barrier. Am J Pathol 2008;172:725-737.
91. Fabriek BO, et al. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 2005;51:297-305.
92. Westmoreland SV, Halpern E, Lackner AA. Simian immunodeficiency virus encephalitis in rhesus macaques is associated with rapid disease progression. J Neurovirol 1998;4:260-268.
93. Lane JH, et al. Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular macrophages/microglia and intrathecal immune activation. J Neurovirol 1996;2:423-432.
94. Esiri MM, Morris CS. Immunocytochemical study of macrophages and microglial cells and extracellular matrix components in human CNS disease. 2. Non-neoplastic diseases. J Neurol Sci 1991;101:59-72.
95. Cassol E, Cassetta L, Alfano M, Poli G. Macrophage polarization and HIV-1 infection. J Leukoc Biol 2010;87:599-608.
96. Bruck W, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788-796.
97. Whitelaw DM. Observations on human monocyte kinetics after pulse labeling. Cell Tissue Kinet 1972;5:311-317.
98. Stossel TP. Phagocytosis (third of three parts). N Engl J Med 1974;290:833-839.
99. van Furth R, Raeburn JA, van Zwet TL. Characteristics of human mononuclear phagocytes. Blood 1979;54:485-500.
100. van Furth R. Origin and turnover of monocytes and macrophages. Curr Top Pathol 1989;79:125-150.
101. Ohgami M, Doerschuk CM, Gie RP, English D, Hogg JC. Monocyte kinetics in rabbits. J Appl Physiol 1991;70:152-157.
102. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012;12:623-635.
103. Prinz M, Priller J, Sisodia SS, Ransohoff RM. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 2011;14:1227-1235.
104. Ransohoff RM. Microglia and monocytes: 'tis plain the twain meet in the brain. Nat Neurosci 2011;14:1098-1100.
105. Hickey WF, Vass K, Lassmann H. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. J Neuropathol Exp Neurol 1992;51:246-256.
106. Lawson LJ, Perry VH, Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 1992;48:405-415.
107. Unger ER, Sung JH, Manivel JC, Chenggis ML, Blazar BR, Krivit W. Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study. J Neuropathol Exp Neurol 1993;52:460-470.
108. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005;308:1314-1318.
109. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988;239:290-292.
110. Stoll G, Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol 1999;58:233-247.
111. Soulas C, Donahue RE, Dunbar CE, Persons DA, Alvarez X, Williams KC. Genetically modified CD34+ hematopoietic stem cells contribute to turnover of brain perivascular macrophages in long-term repopulated primates. Am J Pathol 2009;174:1808-1817.
112. An DS, et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA 2007;104:13110-13115.
113. Poles MA, Elliott J, Taing P, Anton PA, Chen IS. A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol 2001;75:8390-8399.
114. Salemi M, Lamers SL, Yu S, de Oliveira T, Fitch WM, McGrath MS. Phylodynamic analysis of human immunodeficiency virus type 1 in distinct brain compartments provides a model for the neuropathogenesis of AIDS. J Virol 2005;79:11343-11352.
115. Burkala EJ, He J, West JT, Wood C, Petito CK. Compartmentalization of HIV-1 in the central nervous system: role of the choroid plexus. AIDS 2005;19:675-684.
116. Strickland SL, et al. Efficient transmission and persistence of low frequency SIVmac251 variants in CD8-depleted rhesus macaques with different neuropathology. J Gen Virol 2012;93:925-938.
117. Lamers SL, Gray RR, Salemi M, Huysentruyt LC, McGrath MS. HIV-1 phylogenetic analysis shows HIV-1 transits through the meninges to brain and peripheral tissues. Infect Genet Evolution 2011;11:31-37.
118. Strickland SL, et al. Significant genetic heterogeneity of the SIVmac251 viral swarm derived from different sources. AIDS Res Hum Retroviruses 2011;27:1327-1332.
119. Williams K, et al. Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest 2005;115:2534-2545.
120. Campbell JH, et al. Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS. PLoS ONE 2011;6:e18688.
121. Ratai EM, et al. Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS. PLoS ONE 2011;5:e10523.
122. Campbell J, et al. VLA-4 treatment blocks virus traffic to the gut and brain early, and stabilizes CNS injury late in infection. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, 2013.
123. Walker BD, Hirsch MS. Antiretroviral therapy in early HIV infection. N Engl J Med 2013;368:279-281.
124. Breed MW, et al. Loss of a tyrosine-dependent trafficking motif in the simian immunodeficiency virus envelope cytoplasmic tail spares mucosal CD4 cells but does not prevent disease progression. J Virol 2013;87:1528-1543.
125. Sacktor N, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 2011;77:1135-1142.
126. Nakasujja N, et al. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology 2013;80:196-202.
127. Roberts RO, et al. Cardiac disease associated with increased risk of nonamnestic cognitive impairment: stronger effect on women. JAMA Neurol 2013;70:374-382.
128. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010;87:589-598.
129. Hearps AC, Angelovich TA, Jaworowski A, Mills J, Landay AL, Crowe SM. HIV infection and aging of the innate immune system. Sex Health 2011;8:453-464.
130. Smith R, de Boer RJ, Brul S, Budovskaya Y, van der Spek H. Premature and accelerated aging: HIV or HAART? Front Genet 2012;3:1-10.
131. Martin GE, et al. Age-Associated Changes in Monocyte and Innate Immune Activation Markers Occur More Rapidly in HIV Infected Women. PLoS ONE 2013;8:e55279.
132. Brenchley JM, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
133. Parrinello CM, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis 2012;205:1788-1796.
134. Sacre K, et al. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS 2012;26:805-814.
135. Naeger DM, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS ONE 2010;5:e8886.
136. Ling B, et al. The large intestine as a major reservoir for simian immunodeficiency virus in macaques with long-term, nonprogressing infection. J Infect Dis 2010;202:1846-1854.
137. Veazey RS, Lackner AA. Impact of antiretroviral therapy on intestinal lymphoid tissues in HIV infection. PLoS Med 2006;3:e515.
138. Letendre S, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70.
139. Aquaro S, Calio R, Balzarini J, Bellocchi MC, Garaci E, Perno CF. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002;55:209-225.
140. Perno CF, Svicher V, Schols D, Pollicita M, Balzarini J, Aquaro S. Therapeutic strategies towards HIV-1 infection in macrophages. Antiviral Res 2006;71:293-300.
141. Smurzynski M, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011;25:357-365.
142. Fitch KV, et al. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr 2010;55:495-499.
143. Lo J, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010;24:243-253.
144. Grammas P, Martinez J, Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med 2011;13:e19.
145. Cross SA, et al. Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection. J Immunol 2011;187:5015-5025.
146. Burdo T, Blitzer J, McKearn J, Miller A, McGrath M, Williams K. Treatment of SIV+ monkeys with a polyamine biosynthesis inhibitor, PA300 that decreases monocyte activation and infection, blocks AIDS and SIVE. 19th Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, Washington: Washington State Convention Center, 2012.